================================================================================ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 -------------------------------------------------------------------------------- FORM 8-K -------------------------------------------------------------------------------- CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2008 Pharmion Corporation (Exact name of Registrant as specified in its charter) Delaware 000-50447 84-1521333 (State or other jurisdiction of (Commission File Number) (IRS Employer incorporation) Identification No.) 2525 28th Street, Boulder, Colorado 80301 (Address of principal executive offices) (Zip Code) 720-564-9100 (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2 below): [ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) [ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) ================================================================================ Item 8.01 Other Events. On February 7, 2008, Pharmion Corporation ("Pharmion" or the "Company") announced that the European Medicines Agency has accepted for review the Company's Marketing Authorization Application for Vidaza (R) (azacitidine for injection) in patients with higher-risk myelodysplastic syndromes and announced its intent to review the application under the Accelerated Assessment Procedure. The press release is attached hereto as an exhibit and is incorporated by reference herein. Item 9.01 Financial Statements and Exhibits. (d) Exhibit 99.1 Press Release issued by Pharmion Corporation, dated February 7, 2008 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 7, 2008 PHARMION CORPORATION By: /s/ Steven N. Dupont ------------------------------ Name: Steven N. Dupont Title: Executive Vice President and General Counsel EXHIBIT INDEX Exhibit No. Description ----------- ----------- Exhibit 99.1 Press Release issued by Pharmion Corporation, dated February 7, 2008